101 related articles for article (PubMed ID: 31381497)
1. Effective Neutralizing Antibody Produced in Mice Directly Immunized with Integrated
Xv Z; Lv J; Jiang J; Wang W; Feng F; Zhang L; Xue X; Li W
Viral Immunol; 2019 Sep; 32(7):308-317. PubMed ID: 31381497
[TBL] [Abstract][Full Text] [Related]
2. Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.
Hanumantha Rao N; Baji Babu P; Rajendra L; Sriraman R; Pang YY; Schiller JT; Srinivasan VA
Vaccine; 2011 Oct; 29(43):7326-34. PubMed ID: 21803095
[TBL] [Abstract][Full Text] [Related]
3. Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania.
Bolhassani A; Muller M; Roohvand F; Motevalli F; Agi E; Shokri M; Rad MM; Hosseinzadeh S
Hum Vaccin Immunother; 2014; 10(12):3499-508. PubMed ID: 25668661
[TBL] [Abstract][Full Text] [Related]
4. [Humoral immune response and in vitro neutralizing antibody assay on co-delivery of protein HPV16L1 virus-like particle with HPV16L1 gene].
Song JM; Sun XL; Wang YL; Guo JF; Liu TJ; Si LS
Zhonghua Bing Li Xue Za Zhi; 2005 Jul; 34(7):421-4. PubMed ID: 16251048
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine.
Gupta G; Giannino V; Rishi N; Glueck R
Vaccine; 2016 Sep; 34(39):4724-4731. PubMed ID: 27523740
[TBL] [Abstract][Full Text] [Related]
6. [Immune response induced by vaccination with pseudotyped rAAV1 expressing HPV16 L1 protein].
Zhou YB; Li ZL; Zhou L; Sheng W; Ma HT; Zeng Y
Bing Du Xue Bao; 2008 Jul; 24(4):300-4. PubMed ID: 18780634
[TBL] [Abstract][Full Text] [Related]
7. HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.
Yan X; Wang D; Liang F; Fu L; Guo C
Hum Vaccin Immunother; 2014; 10(12):3491-8. PubMed ID: 25483698
[TBL] [Abstract][Full Text] [Related]
8. Physicochemical characterization and immunological properties of Pichia pastoris based HPV16L1 and 18L1 virus like particles.
Gupta G; Glueck R; Rishi N
Biologicals; 2017 Mar; 46():11-22. PubMed ID: 28012703
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity.
Schellenbacher C; Huber B; Skoll M; Shafti-Keramat S; Roden RBS; Kirnbauer R
Vaccine; 2019 Jun; 37(27):3529-3534. PubMed ID: 31147274
[TBL] [Abstract][Full Text] [Related]
11. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
[TBL] [Abstract][Full Text] [Related]
12. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N
Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197
[TBL] [Abstract][Full Text] [Related]
13. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
[TBL] [Abstract][Full Text] [Related]
14. VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris.
Sanchooli A; Aghaiypour K; Kiasari BA; Samarbaf-Zadeh A; Ghadiri A; Makvandi M
Protein Pept Lett; 2018; 25(8):783-790. PubMed ID: 30091403
[TBL] [Abstract][Full Text] [Related]
15. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
16. Transgenic tobacco expressed HPV16-L1 and LT-B combined immunization induces strong mucosal and systemic immune responses in mice.
Hongli L; Xukui L; Ting L; Wensheng L; Lusheng S; Jin Z
Hum Vaccin Immunother; 2013 Jan; 9(1):83-9. PubMed ID: 23108357
[TBL] [Abstract][Full Text] [Related]
17. Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer.
Echchannaoui H; Bianchi M; Baud D; Bobst M; Stehle JC; Nardelli-Haefliger D
Infect Immun; 2008 May; 76(5):1940-51. PubMed ID: 18332214
[TBL] [Abstract][Full Text] [Related]
18. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
Chen Y; Liu Y; Zhang G; Wang A; Dong Z; Qi Y; Wang J; Zhao B; Li N; Jiang M
Virus Res; 2016 Jul; 220():97-103. PubMed ID: 27107614
[TBL] [Abstract][Full Text] [Related]
20. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]